TITLE

Bulking up in generics

AUTHOR(S)
Mirasol, Feliza
PUB. DATE
March 2006
SOURCE
Chemical Market Reporter;3/13/2006, Vol. 269 Issue 10, p18
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the mergers and acquisitions (M&A) of companies in the generic drug industry worldwide. In 2000, leading consolidations were Novartis' Sandoz, Teva Pharmaceuticals and Merck KGaA. Decision Resources Inc. cited the factors driving the boom of M&A activity including cost pressures due to government price regulation, quests for size and economies of scale of companies and the need to access for new therapeutic areas and new technologies.
ACCESSION #
20204028

 

Related Articles

  • Pharma sector to grow at 13%.  // Chemical Business;Mar2007, Vol. 21 Issue 3, p78 

    The article offers information on a study by IndusView on the pharmaceutical industry in India. According to the study, the domestic pharmaceutical industry is expected to grow 13% and reach a market size of $6.5 billion. Topics discussed include low cost, high volume generic drugs, mergers and...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Novartis divests products for Hexal deal.  // Chemical Market Reporter;5/23/2005, Vol. 267 Issue 21, p20 

    The article informs that pharmaceutical firm Novartis AG is set to divest a handful of products in selected European markets as part of concessions made to gain approval from European regulatory authorities for Novartis's proposed acquisition of German generics company, Hexal AG. Novartis...

  • Report from: Japan. Wan, Jane // Pharmaceutical Technology;May2009, Vol. 33 Issue 5, p18 

    The article focuses on the efforts of the Japanese government in implementing generic drugs and its impact to the healthcare system in Japan. It mentions that generic drug substitution was introduced to the public in April 2006 and cites the cooperation of doctors in rendering prescriptions and...

  • Generic Drugs Face Regulatory and Scientific Challenges. Wechsler, Jill // BioPharm International;Aug2013, Vol. 26 Issue 8, p10 

    The article discusses legislative, regulatory and scientific challenges facing the generic drugs sector. The developments in the sector as the U.S. Food and Drug Administration (FDA) celebrates the one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 are discussed. The...

  • Go Go Generics.  // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p24 

    The article discusses developments in the market for generic drugs since the introduction of the Hatch-Waxman Act in the U.S. in 1984. It mentions that generics comprised 70 percent of prescription drugs in the country which are promoted by health plan providers and pharmacy benefit managers...

  • Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Farfan-Portet, MarĂ­a-Isabel; Gerkens, Sophie; Lepage-Nefkens, Isabelle; Vinck, Irmgard; Hulstaert, Frank // European Journal of Health Economics;Apr2014, Vol. 15 Issue 3, p223 

    The article reflects on whether biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures. It is said that a brief reminder of the differences between generics and biosimilars is required before presenting evidence on biosimilar competition. It is also said that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics